Berry Global has announced the launch of the RS01X connected dry powder inhaler, a new version of its RS01 single dose DPI that integrates with Amiko’s Respiro inhaler monitoring platform. The RS01X includes an integral battery and does not require charging, the company said. The Respiro platform, which received the CE mark for use with the Spiromax, Nexthaler, and Ellipta inhalers in 2018, uses artificial intelligence to provide inhaler use suggestions to patients in addition to reminders about when to dose.
Berry Global-Care Unit Managing Director Vincent Clauzel commented, “The introduction of the RS01X is a significant milestone for Berry Healthcare globally, as well as for innovation in respiratory devices. We are very excited to have established a successful and very close partnership with Amiko to achieve this.”
Berry Healthcare Sales and Marketing Director Muriel Combeau added, “The integration of sensing and connectivity into our RS01X inhaler will help to improve patients’ lives, as we bring together the power of digital technology and data science with the premier platform for inhalation technology.”
Amiko Chief Commercial Officer Martijn Grinovero said, “At Amiko, we’ve been consistent in our goal of developing technologies that advance respiratory care. We are thrilled to have found a partner with the vision, ambition and market experience of Berry Global. We are extremely excited about the RS01X and Respiro becoming available to patients and care providers at a scale that truly makes a difference.”
Read the Berry Global press release.
